Reuters logo
BRIEF-Aeterna Zentaris to pursue FDA registration of Macrilen
February 13, 2017 / 12:48 PM / 10 months ago

BRIEF-Aeterna Zentaris to pursue FDA registration of Macrilen

Feb 13 (Reuters) - Aeterna Zentaris Inc

* Aeterna Zentaris announces plans to pursue FDA registration of Macrilen(tm)

* FDA has agreed to consider company’s conclusions during a type a meeting

* Co concluded that macrilen demonstrated performance supportive of achieving registration with U.S. Food and drug administration

* Aeterna Zentaris says co-primary endpoint “negative agreement” with itt, which is considered as more relevant endpoint, was met

* Says co-primary endpoint “positive agreement” with itt was not met Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below